Adjuvax LLC focuses on developing novel saponin-based vaccine adjuvants as a practical alternative to the well-established and FDA-approved saponin adjuvant QS-21.
Adjuvants constitute an indispensable element of modern vaccines because they
enhance the ability of a vaccine to elicit strong and durable immune responses
(including in immunologically compromised individuals), reduce the required antigen dose
and number of immunizations, and modulate the immune response for a specific pathogen.